Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambulatory Oxygen Therapy for Interstitial Lung Disease
NCT06053164Phase 2Recruiting
- Sponsor
- University of Alberta
- Start
- Jul 2025
- Primary completion
- Mar 2027
- Modality
- Inhalation Devices
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of oxygen in interstitial lung disease (ILD) (3 arms), sponsored by University of Alberta. Primary endpoints: Feasibility of investigation at 2 years, Exercise tolerance assessed by 6-Minute Walk Distance and 2 more. Started Jul 2025; status: recruiting.
02
Drugs
oxygen
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT06053164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06053164.